Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10226)	5/27/1999 5:17:00 PM
From: Raul Prytog	Read Replies (1) \| Respond to of 17367

How sure are we that there weren't 62 (or 622 for that matter) who survived AND were not enrolled in the trial? It seems to me that statistical power of the trial, and only the trial will control the findings. I believe that trial-only findings will be excellent.

To: aknahow who wrote (10226)	5/27/1999 5:24:00 PM
From: Bluegreen	Respond to of 17367

SL stated>>>>>The info you gave, fwhco, that the 62 was given to illustrate the difficulty Xoma had in accruing subject due to high mortality before entering the trial: Does this say something about higher Glasgow in the trial, or trouble getting higher Glasgow because of intervening death? Was Xoma able to review excl and incl criteria, get consent from parent, get pt. randomized, get first dose of study in the patient, etc. fast enough in order to adequately fill the high Glasgow stratification to the FDA's satisfaction, or does this not matter? Does the FDA want to know answeres about when and when BPI will and will not work that might be told by the Glasgow?<< THERE YOU GO SL, YES YES YES in my opinion. Let's all keep mulling it over and see what we come up with! Because Xoma has mislead us in the past, could the trial been extended because random entering stratification dispersion wasn't to the FDA's liking?